$196.26
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. The firm operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
Country

US

CEO

Mr. Rainer Blair

IPO date

1969

Employees

58,000

ISIN

US2358511028

Key stats

Open

$196.14

Volume

2.66M

Market cap

$135.02B

Prev. close

$195.98

Impl / hst vl

-

Open interest

$0.00

$196.14

Day’s Range

$196.26

$160.93

52W Range

$242.80

Valuation

44
Valuation score
Fairly Valued
P/E
36.68
P/S
5.46
P/B
2.56
Current ratio
1.87
Debt / Equity
0.24
ROE
7.06%
Gross margin
60.34%
Income growth
-14.04%
FCF growth
-37.86

Jul

31

Dividends

The last payment date was Jul 31, 2026

Div. per Share

$0.40

Div. Yield

0.21%

Payout Ratio

-

Div. Growth YoY

0.00%

Analysts estimates

Consensus rating
Buy

The average rating from top 16 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$244.87
The top 26 analysts forecasts that 12-month price may increase by 24.77%, with a low of $202.00 and a high of $325.50
$202.00
Low
$244.87
Avg
$325.50
High
Current price

Earnings

Q1 ‘26 revenue
$5.95B
Q1 ‘26 net income
$1.03B
Revenue
Net income
Previous EPS
$2.06
Estimate EPS
$1.85
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply